33 completed, 2 terminated, 2 withdrawn. 24 Phase 2, 10 Phase 1, 4 Phase 3, 3 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 20, Terminated 2, Withdrawn 2 |
| Phase 1 | 10 | Completed 9, Terminated 1 |
| Phase 3 | 4 | Completed 4 |
| Not applicable | 3 | Completed 3 |
| Phase 4 | 1 | Completed 1 |
Follow Ligand Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography CE-Iohexol, Iohexol - Contrast-induced Nephropathy | Phase 2 | Withdrawn | Ligand Pharmaceuticals | 2022-01-01 | 2022-04-11 | |
| Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg - Chronic Hepatitis B | Phase 1 | Completed | Nucorion Pharmaceuticals, Inc. | 21 | 2021-01-12 | 2023-01-04 |
| Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects NCO-48 Fumarate, Placebo - Hepatitis B | Phase 1 | Completed | Nucorion Pharmaceuticals, Inc. | 48 | 2020-03-18 | 2020-11-03 |
| Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection Omnipaque™ (iohexol) Injection, CE-Iohexol - Contrast-induced Nephropathy, Coronary Angiography | Not applicable | Completed | CyDex Pharmaceuticals, Inc. | 24 | 2019-04-12 | 2019-08-16 |
| A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus LGD-6972-5 mg, LGD-6972-10 mg, LGD-6972-15 mg - Type 2 Diabetes Mellitus | Phase 2 | Completed | Ligand Pharmaceuticals | 148 | 2016-09-01 | 2018-01-12 |
| A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation LGD-6972 Solution, LGD-6972 Capsules - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Ligand Pharmaceuticals | 12 | 2016-02-01 | 2016-05-18 |
| Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus LGD-6972, Placebo (Captisol ®) - Type 2 Diabetes Mellitus | Phase 1 | Completed | Ligand Pharmaceuticals | 48 | 2014-10-01 | 2015-06-11 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus LGD-6972, Placebo (Captisol®) - Type 2 Diabetes Mellitus | Phase 1 | Completed | Ligand Pharmaceuticals | 56 | 2013-11-01 | 2014-09-25 |
| Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy Intravenous Carbamazepine (IV CBZ) - Epilepsy | Phase 3 | Completed | Lundbeck LLC | 108 | 2010-06-01 | 2018-01-16 |
| Study of MB07811 in Subjects With Hypercholesterolemia MB07811, Placebo - Hypercholesterolemia | Phase 2 | Withdrawn | Ligand Pharmaceuticals | 80 | 2009-04-01 | 2011-08-12 |
| A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension irbesartan, placebo, PS433540 - Hypertension | Phase 2 | Completed | Ligand Pharmaceuticals | 261 | 2008-03-01 | 2011-09-16 |
| The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome Aplindore, Placebo - Restless Legs Syndrome | Phase 2 | Completed | Ligand Pharmaceuticals | 24 | 2008-02-01 | 2011-10-03 |
| Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis Budesonide + Azelastine, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Ligand Pharmaceuticals | 108 | 2008-02-01 | 2012-10-04 |
| The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease Aplindore, Placebo - Early Stage Parkinson's Disease | Phase 2 | Completed | Ligand Pharmaceuticals | 40 | 2008-01-01 | 2011-10-03 |
| A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension PS433540, placebo - Hypertension | Phase 2 | Completed | Ligand Pharmaceuticals | 280 | 2007-08-01 | 2011-09-16 |
| Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus MB07803, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | Ligand Pharmaceuticals | 105 | 2007-03-01 | 2011-10-03 |
| Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR Budesonide, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Ligand Pharmaceuticals | 65 | 2007-02-01 | 2012-10-04 |
| Study of Tarceva and Targretin in Stage I-II Lung Cancer erlotinib (Tarceva) and bexarotene (Targretin) - Carcinoma, Non-small-cell Lung | Not applicable | Completed | Dartmouth-Hitchcock Medical Center | 12 | 2005-12-01 | 2019-01-08 |
| Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer erlotinib and bexarotene - Carcinoma, Non-small-cell Lung | Phase 2 | Completed | Konstantin Dragnev | 42 | 2005-08-01 | 2019-01-08 |
| The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation Lasofoxifene, Placebo - Bone Loss | Phase 2 | Completed | Ligand Pharmaceuticals | 51 | 2004-09-01 | 2011-08-10 |
Showing 20 of 37. Sign in to see all of them.
Diabetes Mellitus, Type 2 (5) · Lymphoma, T-Cell, Cutaneous (4) · Osteoporosis (4) · Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · HIV Infections (3) · Mycosis Fungoides (3) · Sarcoma, Kaposi (3) · Hypertension (2) · Rhinitis, Allergic, Seasonal (2) · Sezary Syndrome (2) · AIDS-Related Opportunistic Infections (1) · Acquired Immunodeficiency Syndrome (1) · Alopecia Areata (1) · Alopecia universalis (1)
Bexarotene (11) · SBE4-beta-cyclodextrin (5) · Lasofoxifene (4) · Erlotinib Hydrochloride (3) · RVT-1502 (3) · Alitretinoin (2) · Budesonide (2) · Iohexol (2) · aplindore fumarate (2) · denileukin diftitox (2) · 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane (1) · 4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (1) · Carbamazepine (1) · Dexamethasone (1) · Gefitinib (1)
United States (28) · Canada (4) · Hong Kong (2) · Japan (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Costa Rica (1) · Croatia (1) · Denmark (1) · Egypt (1)
Deepen Patel, MD (2) · Keith Marschke, Ph.D. (2) · Keith Marschke, PhD (2) · Konstantin H Dragnev, MD (2) · Charlotte D Jacobs (1) · Douglas K Logan, M.D. (1) · Francine Foss, M.D. (1) · George D. Demetri, MD (1) · Isabela Niculae, MPH (1) · James R Rigas, MD (1) · Joel M Neutel, MD (1) · Joel Neutel, MD (1) · Keith Marschke (1)
PMID 12637463, PMID 17515522, PMID 20181970, PMID 20937977, PMID 25912051, PMID 31694861